{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:32:27Z","timestamp":1761226347326,"version":"build-2065373602"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2019MC059","ZR2021QH367"],"award-info":[{"award-number":["ZR2019MC059","ZR2021QH367"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.drudis.2023.103833","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:43:57Z","timestamp":1700527437000},"page":"103833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ligands and receptors in human cytomegalovirus entry: Current therapies and new directions"],"prefix":"10.1016","volume":"29","author":[{"given":"Min","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianshe","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fujun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-097X","authenticated-orcid":false,"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2023.103833_b0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730765","article-title":"Immune landscape of CMV infection in cancer patients: from \u201ccanonical\u201d diseases toward virus-elicited oncomodulation","volume":"12","author":"El Baba","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2023.103833_b0010","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.3390\/biomedicines10102634","article-title":"Atherosclerosis by virus infection\u2013a short review","volume":"10","author":"Jung","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.drudis.2023.103833_b0015","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3389\/fmicb.2020.00661","article-title":"Tuning the orchestra: HCMV vs. innate immunity","volume":"11","author":"Dell'Oste","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.drudis.2023.103833_b0020","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1462-5822.2006.00745.x","article-title":"Systems biology of virus entry in mammalian cells","volume":"8","author":"Damm","year":"2006","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.drudis.2023.103833_b0025","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3389\/fmicb.2020.01511","article-title":"Human cytomegalovirus primary infection and reactivation: insights from virion-carried molecules","volume":"11","author":"Wang","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.drudis.2023.103833_b0030","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01339-16","article-title":"Importance of highly conserved peptide sites of human cytomegalovirus gO for formation of the gH\/gL\/gO complex","volume":"91","author":"Stegmann","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103833_b0035","doi-asserted-by":"crossref","first-page":"11638","DOI":"10.1128\/JVI.05659-11","article-title":"Human cytomegalovirus glycoprotein gO complexes with gH\/gL, promoting interference with viral entry into human fibroblasts but not entry into epithelial cells","volume":"85","author":"Vanarsdall","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103833_b0040","doi-asserted-by":"crossref","first-page":"8999","DOI":"10.1128\/JVI.01325-15","article-title":"Human cytomegalovirus gH\/gL\/gO promotes the fusion step of entry into all cell types, whereas gH\/gL\/UL128-131 broadens virus tropism through a distinct mechanism","volume":"89","author":"Zhou","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103833_b0045","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1073\/pnas.1424818112","article-title":"Structural and biochemical studies of HCMV gH\/gL\/gO and Pentamer reveal mutually exclusive cell entry complexes","volume":"112","author":"Ciferri","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2023.103833_b0050","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nmicrobiol.2016.82","article-title":"Platelet-derived growth factor-alpha receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer","volume":"1","author":"Kabanova","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.drudis.2023.103833_b0055","doi-asserted-by":"crossref","first-page":"8191","DOI":"10.1128\/JVI.72.10.8191-8197.1998","article-title":"The human cytomegalovirus UL74 gene encodes the third component of the glycoprotein H-glycoprotein L-containing envelope complex","volume":"72","author":"Huber","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103833_b0060","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00896-18","article-title":"The human cytomegalovirus endoplasmic reticulum-resident glycoprotein UL148 activates the unfolded protein response","volume":"92","author":"Siddiquey","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103833_b0065","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00688-18","article-title":"Human cytomegalovirus tropism modulator UL148 interacts with SEL1L, a cellular factor that governs endoplasmic reticulum-associated degradation of the viral envelope glycoprotein gO","volume":"92","author":"Nguyen","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103833_b0070","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1099\/jgv.0.001137","article-title":"Differences in the effects of mutations in GP131, a guinea pig cytomegalovirus homologue of pentameric complex component UL130, on macrophage and epithelial cell infection","volume":"99","author":"Miura","year":"2018","journal-title":"J Gen Virol"},{"key":"10.1016\/j.drudis.2023.103833_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005230","article-title":"Antigenic characterization of the HCMV gH\/gL\/gO and pentamer cell entry complexes reveals binding sites for potently neutralizing human antibodies","volume":"11","author":"Ciferri","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2023.103833_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-10-1","article-title":"Alphaherpesvirinae and Gammaherpesvirinae glycoprotein L and CMV UL130 originate from chemokines","volume":"10","author":"Malkowska","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.drudis.2023.103833_b0085","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01336-18","article-title":"The human cytomegalovirus trimer and pentamer promote sequential steps in entry into epithelial and endothelial cells at cell surfaces and endosomes","volume":"92","author":"Liu","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103833_b0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007452","article-title":"Different functional states of fusion protein gB revealed on human cytomegalovirus by cryo electron tomography with Volta phase plate","volume":"14","author":"Si","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2023.103833_b0095","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00205-17","article-title":"Loss of the human cytomegalovirus US16 protein abrogates virus entry into endothelial and epithelial cells by reducing the virion content of the pentamer","volume":"91","author":"Luganini","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103833_b0100","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1128\/JVI.06310-11","article-title":"The US16 gene of human cytomegalovirus is required for efficient viral infection of endothelial and epithelial cells","volume":"86","author":"Bronzini","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103833_b0105","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00332-13","article-title":"Human cytomegalovirus (HCMV) glycoprotein gB promotes virus entry in trans acting as the viral fusion protein rather than as a receptor-binding protein","volume":"4","author":"Wille","year":"2013","journal-title":"mBio"},{"key":"10.1016\/j.drudis.2023.103833_b0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002172","article-title":"B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies","volume":"7","author":"Potzsch","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2023.103833_b0115","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/infdis\/163.6.1229","article-title":"Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes","volume":"163","author":"Chou","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.drudis.2023.103833_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006281","article-title":"Human cytomegalovirus glycoprotein complex gH\/gL\/gO uses PDGFR-alpha as a key for entry","volume":"13","author":"Wu","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2023.103833_b0125","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.cell.2018.06.028","article-title":"An unbiased screen for human cytomegalovirus identifies neuropilin-2 as a central viral receptor","volume":"174","author":"Martinez-Martin","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2023.103833_b0130","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2466\/pms.1988.66.1.144","article-title":"Accuracy of estimations of body-frame size as a function of sex and actual frame size","volume":"66","author":"Hearns","year":"1988","journal-title":"Percept Mot Skills"},{"key":"10.1016\/j.drudis.2023.103833_b0135","doi-asserted-by":"crossref","first-page":"7043","DOI":"10.1073\/pnas.1814850116","article-title":"OR14I1 is a receptor for the human cytomegalovirus pentameric complex and defines viral epithelial cell tropism","volume":"116","author":"E","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2023.103833_b0140","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm2546","article-title":"Structural basis for HCMV pentamer recognition by neuropilin 2 and neutralizing antibodies","volume":"8","author":"Wrapp","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2023.103833_b0145","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm2536","article-title":"Structural basis for HCMV Pentamer receptor recognition and antibody neutralization","volume":"8","author":"Kschonsak","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2023.103833_b0150","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3390\/v13030474","article-title":"Small molecules\u2013prospective novel HCMV inhibitors","volume":"13","author":"Bogner","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2023.103833_b0155","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/GRF.0b013e3182510b7b","article-title":"Prevention of maternal and congenital cytomegalovirus infection","volume":"55","author":"Johnson","year":"2012","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.drudis.2023.103833_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.09.004","article-title":"Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review","volume":"342","author":"Ariza-Heredia","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drudis.2023.103833_b0165","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1186\/s12879-022-07537-6","article-title":"Detection of antiviral drug resistance in patients with congenital cytomegalovirus infection using long-read sequencing: a retrospective observational study","volume":"22","author":"Torii","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.drudis.2023.103833_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101427","article-title":"Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era","volume":"50","author":"Pecetta","year":"2020","journal-title":"Semin Immunol"},{"issue":"14","key":"10.1016\/j.drudis.2023.103833_b0175","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1128\/JVI.00121-16","article-title":"Monoclonal antibodies to different components of the human cytomegalovirus (HCMV) pentamer gH\/gL\/pUL128L and trimer gH\/gL\/gO as well as antibodies elicited during primary HCMV infection prevent epithelial cell syncytium formation","volume":"90","author":"Gerna","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103833_b0180","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3389\/fmicb.2019.01005","article-title":"HCMV envelope glycoprotein diversity demystified","volume":"10","author":"Foglierini","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.drudis.2023.103833_b0185","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s42003-022-03294-z","article-title":"Development of broadly neutralizing antibodies targeting the cytomegalovirus subdominant antigen gH","volume":"5","author":"Parsons","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.drudis.2023.103833_b0190","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3390\/v13081467","article-title":"A fully protective congenital CMV vaccine requires neutralizing antibodies to viral pentamer and gB glycoprotein complexes but a pp65 T-cell response is not necessary","volume":"13","author":"Choi","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2023.103833_b0195","article-title":"Modeling human cytomegalovirus-induced microcephaly in human iPSC-derived brain organoids","volume":"1","author":"Sun","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.drudis.2023.103833_b0200","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.3390\/ijms21175997","article-title":"Convalescent immunity to guinea pig cytomegalovirus induces limited cross strain protection against re-infection but high-level protection against congenital disease","volume":"21","author":"Choi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2023.103833_b0205","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00430-022-00747-4","article-title":"Human cytomegalovirus (HCMV) long-term shedding and HCMV-specific immune response in pregnant women with primary HCMV infection","volume":"211","author":"Fornara","year":"2022","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.drudis.2023.103833_b0210","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1073\/pnas.1814835116","article-title":"HCMV trimer- and pentamer-specific antibodies synergize for virus neutralization but do not correlate with congenital transmission","volume":"116","author":"Vanarsdall","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2023.103833_b0215","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02422-20","article-title":"Potent bispecific neutralizing antibody targeting glycoprotein B and the gH\/gL\/pUL128\/130\/131 complex of human cytomegalovirus","volume":"65","author":"Su","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103833_b0220","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1128\/AAC.00382-16","article-title":"In vitro characterization of human cytomegalovirus-targeting therapeutic monoclonal antibodies LJP538 and LJP539","volume":"60","author":"Patel","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103833_b0225","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1128\/AAC.02698-15","article-title":"A first-in-human study to assess the safety and pharmacokinetics of monoclonal antibodies against human cytomegalovirus in healthy volunteers","volume":"60","author":"Dole","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103833_b0230","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02467-19","article-title":"Phase 2 study of anti-human cytomegalovirus monoclonal antibodies for prophylaxis in hematopoietic cell transplantation","volume":"64","author":"Maertens","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103833_b0235","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1128\/AAC.00523-15","article-title":"Phase 1 randomized, double-blind, Placebo-controlled study of RG7667, an anticytomegalovirus combination monoclonal antibody therapy, in healthy adults","volume":"59","author":"Ishida","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103833_b0240","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01794-16","article-title":"Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk kidney transplant recipients","volume":"61","author":"Ishida","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103833_b0245","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1128\/JVI.00467-12","article-title":"Antibodies against the gH\/gL\/UL128\/UL130\/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin","volume":"86","author":"Fouts","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103833_b0250","doi-asserted-by":"crossref","first-page":"9075","DOI":"10.1016\/j.vaccine.2011.09.056","article-title":"Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.drudis.2023.103833_b0255","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2023.103833_b0260","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.drudis.2023.103833_b0265","article-title":"Characterization of antigen adjuvant interactions in polyacrylate adjuvanted vaccines","volume":"33","author":"Dinadayala","year":"2023","journal-title":"Biochem Biophys Rep"},{"key":"10.1016\/j.drudis.2023.103833_b0270","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41467-023-36683-x","article-title":"The cytomegalovirus gB\/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread","volume":"14","author":"Gomes","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2023.103833_b0275","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijbiomac.2022.10.105","article-title":"CRM197-conjugated multi antigen dominant epitope for effective human cytomegalovirus vaccine development","volume":"224","author":"Jiang","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2023.103833_b0280","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1093\/nar\/12.10.4063","article-title":"The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197","volume":"12","author":"Giannini","year":"1984","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2023.103833_b0285","first-page":"213","volume":"18","author":"Denax","year":"1989","journal-title":"J Gynecol Obstet Biol Reprod"},{"key":"10.1016\/j.drudis.2023.103833_b0290","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ijbiomac.2021.08.177","article-title":"Conjugation of Zika virus EDIII with CRM(197), 8-arm PEG and mannan for development of an effective Zika virus vaccine","volume":"190","author":"He","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2023.103833_b0295","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1016\/j.vaccine.2018.08.054","article-title":"Analysis of relationships between polymorphisms in the genes encoding the pentameric complex and neutralization of clinical cytomegalovirus isolates","volume":"36","author":"Kobayashi","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.drudis.2023.103833_b0300","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41541-021-00342-3","article-title":"A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial","volume":"6","author":"Li","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.drudis.2023.103833_b0305","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01442-19","article-title":"Inclusion of the viral pentamer complex in a vaccine design greatly improves protection against congenital cytomegalovirus in the guinea pig model","volume":"93","author":"Choi","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103833_b0310","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3390\/v14040760","article-title":"Cross strain protection against cytomegalovirus reduces DISC vaccine efficacy against CMV in the guinea pig model","volume":"14","author":"Choi","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2023.103833_b0315","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01012-18","article-title":"Multiantigenic Modified Vaccinia virus Ankara vaccine vectors to elicit potent humoral and cellular immune reponses against human cytomegalovirus in mice","volume":"92","author":"Chiuppesi","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103833_b0320","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jviromet.2017.10.006","article-title":"Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex","volume":"251","author":"Wussow","year":"2018","journal-title":"J Virol Methods"},{"key":"10.1016\/j.drudis.2023.103833_b0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183377","article-title":"Comparison of homologous and heterologous prime\u2013boost vaccine approaches using Modified Vaccinia Ankara and soluble protein to induce neutralizing antibodies by the human cytomegalovirus pentamer complex in mice","volume":"12","author":"Chiuppesi","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2023.103833_b0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004524","article-title":"Human cytomegalovirus vaccine based on the envelope gH\/gL pentamer complex","volume":"10","author":"Wussow","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2023.103833_b0335","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/vaccines7030104","article-title":"Production strategies for pentamer-positive subviral dense bodies as a safe human cytomegalovirus vaccine","volume":"7","author":"Gogesch","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.drudis.2023.103833_b0340","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00931-19","article-title":"Dense bodies of a gH\/gL\/UL128\/UL130\/UL131 pentamer-repaired Towne strain of human cytomegalovirus induce an enhanced neutralizing antibody response","volume":"93","author":"Lehmann","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103833_b0345","article-title":"Protective mechanisms of nonneutralizing antiviral antibodies","volume":"19","author":"Evans","year":"2023","journal-title":"PLOS Pathogens"},{"key":"10.1016\/j.drudis.2023.103833_b0350","first-page":"285","article-title":"Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality","volume":"2","author":"Zhou","year":"2023","journal-title":"Acta Mater Med"},{"key":"10.1016\/j.drudis.2023.103833_b0355","doi-asserted-by":"crossref","first-page":"134","DOI":"10.32607\/actanaturae.10983","article-title":"Synthesis and antiviral properties of 1-substituted 3-[omega-(4-oxoquinazolin-4(3H)-yl)alkyl]uracil derivatives","volume":"12","author":"Paramonova","year":"2020","journal-title":"Acta Nat"},{"key":"10.1016\/j.drudis.2023.103833_b0360","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.antiviral.2019.01.010","article-title":"Antiviral activity spectrum of phenoxazine nucleoside derivatives","volume":"163","author":"Kozlovskaya","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2023.103833_b0365","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2018.01.015","article-title":"Metal-chelating 3-hydroxypyrimidine-2,4-diones inhibit human cytomegalovirus pUL89 endonuclease activity and virus replication","volume":"152","author":"Wang","year":"2018","journal-title":"Antiviral Res"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623003495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623003495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:08:47Z","timestamp":1761224927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644623003495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1359644623003495"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103833","relation":{},"ISSN":["1359-6446"],"issn-type":[{"type":"print","value":"1359-6446"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ligands and receptors in human cytomegalovirus entry: Current therapies and new directions","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103833"}}